Figure 3.

Notch Inhibition Cooperates with AKT1 to Enhance Cardiac Reprogramming

αMHC-GFP MEFs (or GCaMP MEFs in C) were infected with GHMT or AGHMT, and treated with DMSO (vehicle) or DAPT.

(A) Representative immunostaining images of GFP, α-actinin, and cTnT at day 15 of reprogramming. Scale bar, 200 μm.

(B) Quantification of cells positive for α-actinin and cTnT as determined by immunostaining; n = 3 biological replicates.

(C) Quantification of Ca²⁺ flux-positive cells in GCaMP MEFs at day 15; n = 3 biological replicates.

(D) Percentage of beating cells, relative to the number of input cells; n = 3 biological replicates.

(E) Immunoblot against the Ca²⁺ handling proteins ryanodine receptor (RyR) and SERCA2 at day 15 of reprogramming. Densitometric quantification is shown as the average of every replicate, relative to GAPDH.

Data are presented as mean ± SD. ^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001.